Maximilian Papi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maximilian Papi has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Dal Maso
Istituto Oncologico Veneto IOV IRCCS Padova, Italy
26 shared publications - Alessandro Di Federico
University of Bologna 1 Department of Medical and Surgical Sciences Bologna, Italy
26 shared publications - Andreas Görtz
Vela Diagnostics Germany GmbH, Hamburg, Germany
26 shared publications - Angelo Delmonte
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
26 shared publications - Biagio Ricciuti
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
26 shared publications - Diana Giannarelli
Epidemiology and Biostatistics, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
26 shared publications
Latest Publications
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 9. Median overall survival (A-C) and progression-free survival (B-D) according to MAPK status in NI (A-B) and N-CT (C-D) treatment arm. MAPK1/3 WT (yellow line; n = 26/31) vs MAPK1–3 altered (blue line; n = 48/32). OS: Overall survival; PFS: progression-free survival; WT: wild-type.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 9. Median overall survival (A-C) and progression-free survival (B-D) according to MAPK status in NI (A-B) and N-CT (C-D) treatment arm. MAPK1/3 WT (yellow line; n = 26/31) vs MAPK1–3 altered (blue line; n = 48/32). OS: Overall survival; PFS: progression-free survival; WT: wild-type.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Table 4. Summary of adverse events
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Table 4. Summary of adverse events
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 8. Percentage (A) and number (B) of patients with mutations in genes belonging to MAPK1/3 signaling pathway and (C) an overview of MAPK1/3 pathway mutations and copy number variation.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 8. Percentage (A) and number (B) of patients with mutations in genes belonging to MAPK1/3 signaling pathway and (C) an overview of MAPK1/3 pathway mutations and copy number variation.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Table 6. Clinical characteristics of MAPK1/MAPK3-positive vs -negative patients in the Dana Farber Cancer Institute validation cohort.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Table 6. Clinical characteristics of MAPK1/MAPK3-positive vs -negative patients in the Dana Farber Cancer Institute validation cohort.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 4. Overall survival (A) and progression-free survival (B) according to PD-L1 status. PD-L1 negative (<1%; yellow line, n = 52) vs PD-L1 positive (≥1%; blue line, n = 17).
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 4. Overall survival (A) and progression-free survival (B) according to PD-L1 status. PD-L1 negative (<1%; yellow line, n = 52) vs PD-L1 positive (≥1%; blue line, n = 17).
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S14 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 14. Representative cases of multiplexed immunofluorescence showing two lung squamous cell carcinoma cases with (A) and without (B) MAPK alterations.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S14 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 14. Representative cases of multiplexed immunofluorescence showing two lung squamous cell carcinoma cases with (A) and without (B) MAPK alterations.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 10. Median overall survival (A) and progression-free survival (B) according to MAPK status excluding patients with oncogenic copy number variation. MAPK1/3-negative (yellow line; n = 41) vs MAPK1/3-positive (blue line; n = 33).
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 10. Median overall survival (A) and progression-free survival (B) according to MAPK status excluding patients with oncogenic copy number variation. MAPK1/3-negative (yellow line; n = 41) vs MAPK1/3-positive (blue line; n = 33).
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 2. Median overall survival according to response. NI arm (A) and N-CT arm (B). Patients with PD (purple line) vs SD (green line) vs PR (blue line). (C) Median PFS. NI arm (blue line) vs N-CT arm (red line). NI: nivolumab plus ipilimumab; N-CT: nivolumab plus platinum-based chemotherapy; OS: overall survival; PD: progressive disease; PFS: progression-free survival; PR: partial response; SD: stable disease.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 2. Median overall survival according to response. NI arm (A) and N-CT arm (B). Patients with PD (purple line) vs SD (green line) vs PR (blue line). (C) Median PFS. NI arm (blue line) vs N-CT arm (red line). NI: nivolumab plus ipilimumab; N-CT: nivolumab plus platinum-based chemotherapy; OS: overall survival; PD: progressive disease; PFS: progression-free survival; PR: partial response; SD: stable disease.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 11. Exploratory analysis of OS (A, C, E) and PFS (B, D, F) according the most common alterations reported in MAPK1/MAPK3 signaling pathway, including NF1 (A, B), EGFR family (C, D) and FGFR (E, F) family gene mutations.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 11. Exploratory analysis of OS (A, C, E) and PFS (B, D, F) according the most common alterations reported in MAPK1/MAPK3 signaling pathway, including NF1 (A, B), EGFR family (C, D) and FGFR (E, F) family gene mutations.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 12. Multivariable analysis for overall survival in the SQUINT (A) and combined SQUINT + Dana-Farber Cancer Institute (B) cohorts. Multivariable analysis for progression free survival in the SQUINT (C) and combined SQUINT + Dana-Farber Cancer Institute (D) cohorts.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure 12. Multivariable analysis for overall survival in the SQUINT (A) and combined SQUINT + Dana-Farber Cancer Institute (B) cohorts. Multivariable analysis for progression free survival in the SQUINT (C) and combined SQUINT + Dana-Farber Cancer Institute (D) cohorts.